CORESTEM Inc (166480) - Total Liabilities
Based on the latest financial reports, CORESTEM Inc (166480) has total liabilities worth ₩72.65 Billion KRW (≈ $49.24 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
CORESTEM Inc - Total Liabilities Trend (2014–2024)
This chart illustrates how CORESTEM Inc's total liabilities have evolved over time, based on quarterly financial data. See 166480 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
CORESTEM Inc Competitors by Total Liabilities
The table below lists competitors of CORESTEM Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Banswara Syntex Limited
NSE:BANSWRAS
|
India | Rs6.99 Billion |
|
Idex ASA
OL:IDEX
|
Norway | Nkr5.55 Million |
|
HBR Realty Empreendimentos Imobiliários S.A
SA:HBRE3
|
Brazil | R$3.26 Billion |
|
NetSol Technologies Inc
NASDAQ:NTWK
|
USA | $20.75 Million |
|
Strongpoint ASA
OL:STRO
|
Norway | Nkr529.41 Million |
|
360 Capital Group
AU:TGP
|
Australia | AU$80.96 Million |
|
DIC India Limited
NSE:DICIND
|
India | Rs2.02 Billion |
|
York Timber Holdings Ltd
JSE:YRK
|
South Africa | ZAC1.86 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down CORESTEM Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is CORESTEM Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CORESTEM Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CORESTEM Inc (2014–2024)
The table below shows the annual total liabilities of CORESTEM Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩68.86 Billion ≈ $46.67 Million |
+16.74% |
| 2023-12-31 | ₩58.99 Billion ≈ $39.98 Million |
+58.78% |
| 2022-12-31 | ₩37.15 Billion ≈ $25.18 Million |
-62.55% |
| 2021-12-31 | ₩99.22 Billion ≈ $67.24 Million |
-2.33% |
| 2020-12-31 | ₩101.59 Billion ≈ $68.84 Million |
+263.43% |
| 2019-12-31 | ₩27.95 Billion ≈ $18.94 Million |
+3.43% |
| 2018-12-31 | ₩27.03 Billion ≈ $18.31 Million |
+7.80% |
| 2017-12-31 | ₩25.07 Billion ≈ $16.99 Million |
+32.22% |
| 2016-12-31 | ₩18.96 Billion ≈ $12.85 Million |
+59.12% |
| 2015-12-31 | ₩11.92 Billion ≈ $8.08 Million |
-29.97% |
| 2014-12-31 | ₩17.02 Billion ≈ $11.53 Million |
-- |
About CORESTEM Inc
CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatm… Read more